StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

Investment analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners decreased their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 0.3 %

NASDAQ:AWH opened at $0.75 on Monday. Aspira Women’s Health has a twelve month low of $0.67 and a twelve month high of $5.65. The firm has a market capitalization of $12.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.44. The stock’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $1.31.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.